

**Quantifying the effects of diuretics and beta-blockers on glycaemic control in diabetes  
mellitus - a systematic review and meta-analysis**

**Jennifer A Hirst<sup>1</sup>, Andrew J Farmer<sup>1</sup>, Benjamin G Feakins<sup>1</sup>, Jeffrey K Aronson<sup>1</sup>, Richard J  
Stevens<sup>1</sup>**

<sup>1</sup> Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory  
Quarter, Woodstock Road, Oxford, OX2 6GG, United Kingdom, and National Institute for Health  
Research School for Primary Care Research

Corresponding author:

Jennifer Hirst

Nuffield Department of Primary Care Health Sciences

University of Oxford

Radcliffe Observatory Quarter

Woodstock Road

Oxford, OX2 6GG

United Kingdom

Tel: +44 (0)1865 617945

e-mail: [jennifer.hirst@phc.ox.ac.uk](mailto:jennifer.hirst@phc.ox.ac.uk)

## **Abstract**

Although there are reports that beta-adrenoceptor antagonists (beta-blockers) and diuretics can affect glycaemic control in people with diabetes mellitus, there is no clear information on how blood glucose concentrations may change and by how much. We report results from a systematic review to quantify the effects of these antihypertensive drugs on glycaemic control in adults with established diabetes.

**Methods:** We systematically reviewed the literature to identify randomised controlled trials in which glycaemic control was studied in adults with diabetes taking either beta-blockers or diuretics. We combined data on HbA<sub>1c</sub> and fasting blood glucose using fixed-effects meta-analysis.

**Results:** From 3864 papers retrieved, we found 10 studies of beta-blockers and 12 studies of diuretics to include in the meta-analysis; one study included both comparisons, totalling 21 included reports.

Beta-blockers increased fasting blood glucose concentrations by 0.64 mmol/l (95%CI 0.24 to 1.03) and diuretics by 0.77 mmol/l (95%CI 0.14 to 1.39) compared with placebo. Effect sizes were largest in trials of non-selective beta-blockers (1.33, 95%CI 0.72 to 1.95) and thiazide diuretics (1.69, 95%CI 0.60 to 2.69). Beta-blockers increased HbA<sub>1c</sub> concentrations by 0.75% (95%CI 0.30 to 1.20) and diuretics by 0.24% (95%CI -0.17 to 0.65) compared with placebo. There was no significant difference in the number of hypoglycaemic events between beta-blockers and placebo in three trials.

**Conclusions:** Randomised trials suggest that diuretics and non-selective beta-blockers increase fasting blood glucose and HbA<sub>1c</sub> concentrations in patients with diabetes by moderate amounts. These data will inform prescribing and monitoring of beta-blockers and diuretics in patients with diabetes.

What is known about the subject:

- Antihypertensive medications are commonly used in people with diabetes mellitus.
- Beta-blockers and diuretics may alter blood glucose control but it is not clear how large the effects are.

What this study adds:

- This is the first systematic review of studies of the effects of beta-blockers and diuretics on glycaemic control in diabetes mellitus
- The analysis confirms previous views that non-selective beta-blockers and thiazide diuretics increase fasting blood glucose concentrations in diabetes
- Closer monitoring of glycaemic control for a short time after initiating one of these medications, and adjustment of glucose-lowering therapy if required, would be appropriate

## Introduction

Around 85% of people with diabetes mellitus have co-morbidities that may require them to take other medications (1, 2). While it is important that co-existent risk factors are treated effectively, it is also important for blood glucose control to be maintained. However, many medications are reported to affect blood glucose concentrations or the required dose of insulin. Extensive lists of medications that may adversely affect blood glucose control in people with diabetes are available from both regulatory agencies, such as the European Medicines Agency (EMA (3)), and internet-based information resources (e.g. Diabetes in Control (4) and dLife (5)). Despite evidence that certain drugs affect glycaemic control, the available lists contain neither references to the sources of information nor information about the magnitude of the effect that can be expected when a medication is used. If patients and clinicians had access to information about how medications can affect glycaemic control, they would be able to make informed decisions regarding HbA<sub>1c</sub> monitoring and the type of medication or dosage to use. This could help clinicians to avoid prescribing certain medications that pose higher risks of hypoglycaemia or hyperglycaemia. Alternatively, some drugs that were previously avoided may be found to have minimal effects on blood glucose control and thus be safer to use than originally thought.

We chose to study beta-blockers and diuretics because both are commonly prescribed in diabetes and they have been associated with adverse effects on carbohydrate metabolism (6). Beta-blockers have several different effects on blood glucose control through mechanisms that can oppose each other. For example, they can reduce blood glucose concentrations by blocking the actions of catecholamines in promoting glycogenolysis and gluconeogenesis (7). However, they can also increase blood glucose concentrations by inhibiting the release of insulin from pancreatic  $\beta$ -cells (8), which is mediated by beta<sub>2</sub>-adrenoceptors. Furthermore, beta-blockade also increases growth hormone release in response to growth hormone releasing hormone (9) which would tend to cause hyperglycemia. In children the balance of these actions may result in hypoglycemia (10) and in adults with heart failure hyperglycemia (8).

Several trials have reported that some non-selective vasodilating beta-blockers may have favourable effects on insulin sensitivity and glycaemic control compared with selective beta-blockers (11-13). These trials suggest that some beta-blockers can be used safely in people with diabetes, but at present the available information is conflicting. A meta-analysis comparing the rates of cardiovascular events for people with diabetes taking atenolol compared to other antihypertensive drugs showed an increased risk ratio of 1.12 (95% CI 1.00 to 1.25,  $p=0.06$ ) (14).

Randomised trials have shown that low-dose diuretic treatment prevents major cardiovascular events in people with and without diabetes (15, 16). However, thiazide diuretics have been linked to adverse metabolic effects, glucose intolerance, and hyperglycaemia (17), as well as incident diabetes (18). Some studies have suggested that the use of diuretics in diabetes may be dangerous; for example, a cohort study from 1991 reported that using diuretics to reduce hypertension in diabetes was associated with an increased risk of mortality (19). Diuretics can also cause hypokalaemia (20), which can cause reduced insulin secretion and an increased risk of diabetes (17, 21).

Information on whether these medications have adverse effects on glucose control in people with diabetes is hard to find. Despite its importance in monitoring and care, this information has not to date been systematically assessed, making it difficult for clinicians to make informed decisions about how these medications should be used. We have carried out a systematic review and meta-analysis to quantify the effects of beta-blockers and diuretics on glycaemic control and the incidence of adverse events in people with type 1 and type 2 diabetes.

## **Methods**

Our review and protocol were registered, in advance of searching the literature, on the Prospero database (registration number: CRD42013004261). We searched Medline and EMBASE databases and the Cochrane database of registered controlled trials from 1946 to the end of March 2013 with no language restrictions. In addition, we searched the Clinical trials.gov clinical trials registry and scanned reference lists of reviews and relevant papers for eligible trials. The Medline search strategy

is shown in the on-line appendix. All identified studies were screened independently by two reviewers (JH and BF) for eligibility. We included placebo-controlled randomised trials of any duration in which the effects of either beta-blockers or diuretics on measures of glycaemic control in people with diabetes were assessed. We also included trials in which a diuretic or beta-blocker was added to another medication, provided that the other medication was the same in both the intervention and comparator arms. Two reviewers extracted data on study characteristics (intervention and comparator medications and doses, length of follow-up), patient characteristics (mean age, sex, BMI, and diabetes duration), study quality (randomisation and blinding (22)), and patient outcomes (measures of glycaemic control) from included trials. The primary outcome was glycaemic control, measured as HbA<sub>1c</sub>, fasting blood glucose, or hypoglycaemic episodes between intervention and control groups. Secondary outcomes were systolic blood pressure and adverse events. We wrote to the authors of trials published in the past 10 years to request unpublished data.

The definitions of episodes of symptomatic hypoglycaemia reported in the methods of each paper were accepted as the criteria for our analysis (including tremor, sweating, tachycardia, palpitation, and piloerection). We also extracted data on end-point systolic blood pressure when it was reported. The quality of included studies was assessed, and studies in which randomisation or double blinding were not stated were excluded in a sensitivity analyses to see whether this affected the results. We assessed the potential risk of publication bias using Eggers' test (22).

### *Statistical methods*

All analyses were carried out using Stata 12.1SE (StataCorp, Tx). Fasting blood glucose concentrations that were reported as mg/dl were converted to mmol/l. We pooled data on the mean difference between intervention and comparator groups in fasting blood glucose, HbA<sub>1c</sub> concentrations and systolic blood pressure reported at the end of the trial using a fixed effects inverse variance weighted meta-analysis. HbA<sub>1c</sub> was only pooled in trials that lasted 8 weeks or longer. Numbers of hypoglycaemic events or other adverse events were pooled using the Mantel Haenszel method to calculate the risk ratio (22). When total or mean numbers of adverse events per patient

were reported, we calculated the number of events per patient-week in the trial, to enable pooling of the results. Standard deviations were imputed in one trial in which they were not reported (23) by averaging standard deviations from all the included trials in which they were reported, as recommended in the Cochrane Handbook (22), and the geometric mean was approximated to the mean. Trials in which approximations were made were excluded in a sensitivity analysis. Prespecified sub-group analysis and meta-regression was used to assess whether selective and non-selective beta-blockers (24, 25) gave significantly different results from each other, and whether thiazide diuretics gave significantly different results from other diuretics.

## **Results**

We identified 3864 papers, 188 of which were duplicate reference resulting from searching multiple databases, leaving 3676 papers for review (Figure 1). After review of titles and abstracts, 3587 papers were excluded, leaving 89 papers to be included for full text examination (55 using beta-blockers, 30 using diuretics, and 4 using both). After examining the full texts, we included 21 randomised controlled trials, 10 of beta-blockers (15 comparisons) involving 1889 participants and 12 of diuretics (13 comparisons) with a total of 366 participants; one RCT included both interventions (26). The Clinicaltrials.gov registry yielded a further 157 possible trials, from which no additional trials were identified for inclusion. Several eligible trials were excluded from the analysis because no measure of glycaemic control was reported and data could not be obtained from the authors (23, 27-32). One comparison of two doses of cyclopenthiazide was also excluded (33). Included trials are shown in Table 1. All but 3 of the included trials were 3 months duration or shorter. The mean trial duration in the ten beta-blocker trials was 17 weeks, all trial participants were adults, and most had type 2 diabetes, were hypertensive, and were not using insulin. The mean trial duration in the eleven diuretic trials was 7.5 weeks with only one trial of longer than 12 weeks, all trial participants were adults, and most had type 2 diabetes, were hypertensive and were not using insulin.

The methodological quality of the included trials was high and most reported obtaining informed consent from participants. Only one beta-blocker trial reported the method of randomisation (34) and

all but two trials (26, 35) reported double blinding. Two trials of diuretics did not clearly report randomisation (36, 37) and three did not report double blinding (26, 37, 38).

### Beta-blockers

Of the trials of beta-blockers, six (seven comparisons) reported fasting blood glucose concentrations (696 participants). Beta-blockers increased pooled end-point fasting blood glucose by 0.64 mmol/l (95% CI 0.24 to 1.03) compared with placebo (Figure 2). Four trials (five comparisons) of non-selective beta-blockers (propranolol and celiprolol) had a significantly larger pooled effect size than 2 trials of selective beta-blockers (atenolol and nebivolol) (1.33 mmol/l, 95% CI 0.72 to 1.95 compared with 0.15 mmol/l, 95% CI -0.36 to 0.66) ( $p=0.034$ ). Pooling data from five comparison arms of one trial that reported HbA<sub>1c</sub> showed that beta-blockers increased HbA<sub>1c</sub> by 0.75% (95% CI 0.30 to 1.20), corresponding to 8.2 mmol/mol (95% CI 3.3 to 13.1) compared with placebo (On-line appendix Figure A1), with no difference between selective and non-selective beta-blockers (results not shown). Four trials (9 comparisons) reported blood pressure; pooling end-point data showed that systolic blood pressure was 8 mmHg (95% CI 4 to 13) lower in patients who had taken beta-blockers compared with placebo. Sensitivity analyses excluding trials that were not double-blind did not substantially change the results. Three trials reported the numbers of hypoglycaemic events; the pooled data showed that there was no significant difference in the numbers of events between those who took beta-blockers and those who did not; risk ratio 0.80 (95% CI 0.31 to 2.06). Treatment with beta-blockers resulted in fewer cardiovascular events in 5 trials; RR 0.78 (95% CI 0.68 to 0.90,  $p<0.001$ ), and lower mortality in 4 trials; RR 0.77 (95% CI 0.63 to 0.96,  $p=0.019$ ) compared with control groups. There was no significant difference in the numbers of other adverse events between beta-blockers and the comparator group (appendix Figure A2).

### Diuretics

Eight of the diuretics trials (9 comparisons) reported fasting blood glucose concentrations; pooling the end-point data showed that patients randomised to diuretics had fasting blood glucose concentrations 0.77 mmol/l (95% CI 0.14 to 1.39) higher than those randomised to placebo (Figure 2). The four trials



(5 comparisons) that used thiazide diuretics had a larger effect size than those that used non-thiazide diuretics (1.69, 95% CI 0.69 to 2.69, and 0.18, 95% CI -0.62 to 0.98 respectively), which was of borderline significance ( $p=0.054$ ). Six trials of 8 weeks or longer reported HbA<sub>1c</sub> concentrations; pooling end-point data showed that patients taking diuretics had HbA<sub>1c</sub> concentrations 0.24% higher (95% CI -0.17 to 0.65), corresponding to 2.6 (95% CI -1.9 to 7.1) mmol/mol compared with placebo, but this was not significant ( $p=0.58$ ; On-line appendix Figure A3). Trials of thiazide diuretics showed a slightly greater increase in HbA<sub>1c</sub> than trials of non-thiazide diuretics, but neither result was significant (results not shown). When data from the potassium-sparing diuretic spironolactone were examined separately, the pooled fasting blood glucose was 0.08 mmol/l (95% CI -0.79 to 0.95) higher in 3 trials and HbA<sub>1c</sub> was 0.24% (95% CI -0.39 to 0.88) higher in 2 trials compared with placebo. However, we were unable to assess the extent to which the effect of the thiazides was related to potassium depletion (8), since electrolyte concentrations were not reported in the included studies. Eleven trials (12 comparisons) reported blood pressures; pooling end-point data showed that in patients who took diuretics systolic blood pressure was 12 mmHg (95% CI 10 to 14;  $p<0.0001$ ) lower than with placebo. Sensitivity analyses to exclude trials in which estimations were made and trials that did not clearly report randomisation or double blinding did not substantially change the results for HbA<sub>1c</sub> (data not shown), but did reduce the effect size of diuretics on fasting blood glucose to 0.62 (95% CI -0.15 to 1.40) mmol/l ( $p=0.11$ ). None of the included diuretic trials reported numbers of adverse events. The result from Eggers' test ( $p=0.045$ ) was consistent with possible publication bias for trials reporting fasting blood glucose.

## **Discussion**

We have found that both beta-blockers and diuretics, in doses that are highly effective in lowering blood pressure, significantly increase fasting blood glucose in adults with diabetes mellitus. The effect of beta-blockers was most clearly seen in studies of non-selective beta-blockers (propranolol and celiprolol); the selective beta-blockers atenolol and nebivolol had little effect, although this result was based on only two studies. The effect of diuretics was most clearly seen with thiazide diuretics, which is consistent with reports from studies in individuals without diabetes, in whom thiazide diuretics have

been associated with hyperglycaemia (39). There was only one included study of beta-blockers and HbA<sub>1c</sub>. Across six studies of diuretics there was a modest and non-significant increase in HbA<sub>1c</sub>.

Although antihypertensive medications are widely used in diabetes, this is the first systematic review of the literature with meta-analysis to quantify the extent to which beta-blockers or diuretics affect glycaemic control. Many medications have been reported to affect blood glucose concentrations, but there is very little information to guide clinicians and patients on which are safe to use and which should be avoided in people with diabetes.

We have found that beta-blockers increase fasting blood glucose by around 0.6 mmol/l (1.3 mmol/l for non-selective beta-blockers) and diuretics by around 0.8 mmol/l (1.7 mmol/l for thiazide diuretics). Trials of non-selective beta-blockers increased fasting blood glucose significantly more than those of selective beta-blockers. This is incongruent with some previous reports (11-13, 40). However, non-selective beta-blockers have opposing mechanisms of action on insulin secretion and glucose utilization (41, 42), and the results of this study suggest that in people with diabetes the mechanisms by which beta-blockers cause an overall increase in blood glucose concentration predominate over those that would cause a reduction, and that this effect is primarily mediated via beta<sub>2</sub>-adrenoceptors.

Diuretics on the other hand, probably only affect insulin secretion (17). It is possible that the combined use of diuretics and beta-blockers results in even greater increases in blood glucose concentrations; as evidenced from a single trial in our review which included both agents (26). Since only one of the included trials of diuretics reported any adverse events we are unable to report pooled results for diuretics. We found no evidence of an increase in adverse events with beta-blockers; however, the trials included in our analysis were relatively short (maximum duration 20 months), and it is possible that in the longer term an increased risk of the microvascular and macrovascular complications of diabetes may result from the deterioration in glycaemic control (43). In a minor deviation from the protocol, we included trials of 8 weeks or longer in the meta-analysis of HbA<sub>1c</sub>,

since previous studies have reported that most of the change in HbA<sub>1c</sub> takes place within the first 8 weeks of a medication change (44).

Our systematic review has some limitations; most importantly, several large published trials of beta-blockers or diuretics had to be excluded from the analysis because they did not report outcome data for either HbA<sub>1c</sub> or FBG and we were unable to obtain the data from the authors. If these trials had reported no significant differences in glycaemic control between groups, then our meta-analysis could be overestimating the effect sizes. We have been unable to examine the effect of diuretics on adverse events, as insufficient trials reported these outcomes. Most of the trials we included did not report the method of randomisation, which is a potential source of bias; the impact of this could not be assessed because there were too few trials. We found a significant risk of publication bias in the beta-blocker studies, however we only had 8 and 9 comparisons for beta-blockers and diuretics respectively and Egger's test for publication bias is reported to be unreliable when fewer than 10 trials are compared (22) The results of this analysis should therefore be interpreted with caution. Moreover, all the trials were small, with only one trial included in the analysis of beta-blockers having more than 40 participants and none of the diuretics trials having more than 56 participants. The majority of trials included in our review were of 3 months duration or less; we were therefore unable to assess the longer-term impact of these medications on glycaemic control. Additionally, many of the included trials were old and therefore the generalizability of the findings to present-day practice may be limited. Most of our included studies were carried out in hypertensive patients; there were too few studies in patients with heart failure to enable comparison with patients with hypertension. Of the 21 included trials only 5 reported that doses of blood glucose lowering medications were unchanged for the duration of the trial; 2 beta-blocker trials (35, 45) and 3 diuretic trials (33, 36, 46). We were therefore unable to compare effect sizes in individuals with and without changes to their blood glucose lowering medications, however, the majority of trial participants were taking oral medications, and trial durations were short, which may have limited the opportunities for medication changes. Our analysis of the effects of beta-blockers on HbA<sub>1c</sub> was based on one trial with several arms comparing different beta-blockers; the results from this analysis should therefore be interpreted

with caution. There were too few studies to enable comparisons between individual beta-blockers or diuretics or to compare different doses. However, we were able to compare trials of selective beta-blockers (2 trials) with trials of non-selective beta-blockers (5 trials) and trials of thiazide diuretics (5 trials) with trials of non-thiazide diuretics (4 trials) and spironolactone (3 trials). Although these subgroup analyses were pre-specified, they are indirect comparisons and the results should therefore be interpreted with caution. The results of this review could guide clinicians who are considering prescribing blood pressure-lowering medications for people with diabetes. We have confirmed the existence of glycaemic effects of beta-blockers and diuretics. Although the mean effects appear small, we cannot rule out the possibility of a larger effect in some individuals however we cannot investigate this further because of the parallel group design of the studies included in this review. Until further studies better identify prescriptive and predictive explanations for these variations, the current recommendation - to use other classes of anti-hypertensive agents in diabetes whenever possible - appears well supported by underpinning evidence. Furthermore, closer monitoring of glycaemic control for a short time after initiating one of these medications, and adjustment of glucose-lowering therapy if required, would be appropriate.

### **Competing interests**

All authors have completed the Unified Competing Interest form at [http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author). JH had support from the UK's National Institute for Health Research (NIHR) School for Primary Care Research (SPCR) for the submitted work. This article/paper/report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript; no financial relationships with any organisations that might have an interest in the

submitted work in the previous 3 years AF receives support from the NIHR Oxford Biomedical Research Centre and is an NIHR Senior Investigator.


### **Author contributions**

JH designed the study, performed literature searches, data extraction, and statistical analyses and drafted the manuscript, AF contributed to study design, interpretation of results, and discussion, JKA contributed to study design, interpretation of results, and discussion, BF contributed to data extraction and interpretation of results, RS contributed to study design, interpretation of results, and discussion and provided statistical support. All authors reviewed and edited the manuscript and approved the final version.

### **Acknowledgements**

Thank you to Dr Kasper Rossing for providing us with unpublished data and to Dr Clare Bankhead who assisted in the funding application.

### **Figure 1 – Flow chart of searches**



**Table 1 - List of included studies**

<b>Beta-blockers</b>														
Authors (ref)	Year	Number of participants	Type of diabetes	Insulin use	Setting	Intervention	n	Dose (mg/day)	Comparator	n	Mean age	Duration of diabetes (years)	Length of trial (weeks)	Diabetes medication adjusted?
Chalon (34)	1999	14	ns	yes	hypoglycaemia	propranolol	9	60	placebo	5	40	15.0	4	ns
Chellingworth (35)	1989	19	2	no	hypertension	propranolol	19	160	placebo	19	ns	ns	4	no
Dornhorst (26)	1985	15	2	47%	hypertension	propranolol	15	160	no treatment	15	ns	6.8	3	ns
Lewis (47)	1991	22	2	no	-	propranolol	22	160	placebo	22	59	ns	4	ns
Whitcroft (45)	1990	27	2	no	hypertension	propranolol	27	160	placebo	7	ns	ns	13	no
Dornhorst (26)	1985	15	2	47%	hypertension	propranolol + hydrochlorothiazide	15	160	hydrochlorothiazide	15	ns	6.8	3	ns
Deedwania (48)	2005	985	ns	ns	heart failure	metoprolol	495	160	placebo	490	65	ns	52	ns
Profozic (49)	1997	30	2	no	hypertension	atenolol	20	50	placebo	10	61	6.8	6	no
Whitcroft (45)	1990	27	2	no	hypertension	atenolol	27	100	placebo	7	ns	ns	13	no
Whitcroft (45)	1990	10	2	no	hypertension	atenolol	10	100	placebo	7	ns	ns	13	no
Whitcroft (45)	1990	15	2	no	hypertension	atenolol+ prazosin	14	100	prazosin	15	ns	ns	13	ns
de Boer (50)	2010	555	ns	ns	heart failure	nebivolol	287	10	placebo	268	76	ns	84	ns
Gundersen & Rodda (28, 51, 52)	1983 - 1985	99	ns	ns	acute myocardial infarction	timolol	53	20	placebo	46	ns	ns	74	ns
Larijani (53)	2006	40	2	ns	-	carvedilol	20	18.75	placebo	20	50	6.4	2	ns
Whitcroft (45)	1990	16	2	no	hypertension	nadolol	16	80	placebo	6	ns	ns	13	ns
<b>Diuretics</b>														
Author	Year	Number of participants	Type of diabetes	Insulin use	Setting	Intervention	n	Dose (mg/day)	Comparator	n	Mean age	Duration of diabetes (years)	Length of trial (weeks)	
Davies (54)	2004	42	2	no	-	spironolactone	42	47.5	placebo	42	60	ns	4	ns
Rossing (55)	2005	20	2	ns	diabetic nephropathy	spironolactone	20	25	placebo	20	58	12.0	8	ns
Mehdi (23)	2009	54	15% type 1	ns	diabetic nephropathy	spironolactone	27	25	placebo	27	51	16	48	ns

Schjoedt (56)	2006	20	45% type 1	ns	diabetic nephropathy	spironolactone	20	25	placebo	20	49	21	8	ns
Swaminathan (57)	2008	38	2	no	hypertension	spironolactone	38	25	placebo	38	63	ns	4	ns
Dornhorst (26)	1985	15	2	47%	hypertension	hydrochlorothiazide	15	100	no treatment	15	ns	6.8	3	ns
Klauser (36)	1991	6	2	no	-	hydrochlorothiazide	6	50	placebo	6	57	ns	4	no
Dornhorst (26)	1985	15	2	47%	hypertension	hydrochlorothiazide +propranolol	15	100	propranolol	15	ns	6.8	3	ns
Pacy (37)	1984	50	ns	20%	hypertension	bendroflumethiazide	25	10	diet	25	55	6.5	12	ns
Hunter (46)	1999	11	2	no	hypertension	bendroflumethiazide + captopril	11	2.5	placebo + captopril	11	58	ns	12	no
McLaughlin (58)	2008	15	2	no	hypertension	bendroflumethiazide	15	1.25	placebo	15	53	ns	12	ns
Kuo (38)	2003	56	2	no	hypertension	indapamide	28	1.5	placebo	28	60	ns	12	ns
Passmore (33)	1991	24	2	no	hypertension	cyclopenthiazide	24	0.125	cyclopenthiazide	24	59	ns	12	no

ns – not stated



Figure 2 – Mean difference in end-point fasting blood glucose (mmol/l) with beta-blockers versus placebo (boxes) and pooled estimates (diamond) calculated by the inverse variance fixed effects model. Horizontal bars and diamond widths represent 95% CIs and box sizes indicate relative weights in the analysis





Figure 3 – Mean difference in end-point fasting blood glucose (mmol/l) with diuretics versus placebo (boxes) and pooled estimates (diamond) calculated by the inverse variance fixed effects model.

Horizontal bars and diamond widths represent 95% CIs and box sizes indicate relative weights in the analysis



## References

1. Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. *Diabetol Metab Syndr*. 2013;5(1):57.
2. Luijckx H, Schermer T, Bor H, van Weel C, Lagro-Janssen T, Biermans M, et al. Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study. *BMC Med*. 2012;10:128.
3. EMA. European Medicines Agency - Annex 1 Summary of product characteristics, section 4.5 Interaction with other medicinal products and other forms of interaction. [25 Feb 2013]; Available from: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000441/WC500033307.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000441/WC500033307.pdf)
4. Diabetes-in-Control. Drugs that can affect blood glucose levels. 2011 [25 Feb 2013]; Available from: <http://www.diabetesincontrol.com/images/tools/druglistaffectingbloodglucose.pdf>.
5. dLife. Drugs that affect blood glucose levels. [14 Aug 2012]; Available from: <http://www.dlife.com/diabetes/type-2/diabetes-treatment/drugs-that-raise-blood-glucose>.
6. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. *Drug Saf*. 1996 Aug;15(2):135-57.
7. Popp DA, Shah SD, Cryer PE. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus. *J Clin Invest*. 1982 Feb;69(2):315-26.
8. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. *Int J Cardiol*. 2013 Oct 9;168(4):3572-9.
9. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, et al. Acute hyperglycemia and activation of the beta-adrenergic system exhibit synergistic inhibitory actions on growth hormone (GH) releasing hormone-induced GH release. *Eur J Endocrinol*. 2003 Jun;148(6):635-40.
10. Hussain T, Greenhalgh K, McLeod KA. Hypoglycaemic syncope in children secondary to beta-blockers. *Arch Dis Child*. 2009 Dec;94(12):968-9.
11. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA*. 2004 Nov 10;292(18):2227-36.
12. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. *Ann Intern Med*. 1997 Jun 15;126(12):955-9.
13. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. *J Hypertens*. 1996 Apr;14(4):489-94.
14. Balamuthusamy S, Molnar J, Adigopula S, Arora R. Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis. *Am J Ther*. 2009 Mar-Apr;16(2):133-42.
15. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. *JAMA*. 1996 Dec 18;276(23):1886-92.
16. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. *Am J Cardiol*. 2005 Jan 1;95(1):29-35.
17. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. *Ann Intern Med*. 1993 Apr 1;118(7):529-39.


18. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med*. 2006 Nov 13;166(20):2191-201.
19. Warram JH, Laffel LM, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. *Arch Intern Med*. 1991 Jul;151(7):1350-6.
20. Sander GE, Giles TD. Thiazide diuretics and beta-blockers in the treatment of hypertension in diabetes mellitus. *J Clin Hypertens (Greenwich)*. 2011 Apr;13(4):296-300.
21. Shafi T, Appel LJ, Miller ER, 3rd, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. *Hypertension*. 2008 Dec;52(6):1022-9.
22. Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. In: Higgins J, Green S, editors. 2011.
23. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. *Journal of the American Society of Nephrology*. 2009 Dec;20(12):2641-50.
24. Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of beta blockers: focus on nebivolol. *J Cardiovasc Pharmacol*. 2009 Aug;54(2):123-8.
25. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. *Cardiovasc Drugs Ther*. 1999 Apr;13(2):123-6.
26. Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. *Lancet*. 1985 Jan 19;1(8421):123-6.
27. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. *Journal of the American College of Cardiology*. 2003 Sep 3;42(5):914-22.
28. Gundersen T, Kjekshus J. Timolol-related reduction in mortality and reinfarction in diabetic patients surviving acute myocardial infarction. *Hormone & Metabolic Research - Supplement*. 1985;15:58-60.
29. Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. *Diabetologia*. 1995 Jul;38(7):853-9.
30. Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. *Journal of Cardiovascular Pharmacology*. 1986;8 Suppl 11:S96-9.
31. Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. *European Heart Journal*. 1989 May;10(5):423-8.
32. O'Connor CM, Gottlieb S, Bourque JM, Krause-Steinrauf H, Anand I, Anderson JL, et al. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. *American Journal of Cardiology*. 2005 Mar 1;95(5):558-64.
33. Passmore AP, Whitehead EM, Crawford V, McVeigh GE, Johnston GD. The antihypertensive and metabolic effects of low and conventional dose cyclopentiazide in type II diabetics with hypertension. *Quarterly Journal of Medicine*. 1991 Nov;81(295):919-28.
34. Chalon S, Berlin I, Sachon C, Bosquet F, Grimaldi A. Propranolol in hypoglycaemia unawareness. *Diabetes & Metabolism*. 1999 Mar;25(1):23-6.
35. Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. *Journal of Human Hypertension*. 1989 Feb;3(1):35-9.
36. Klauser R, Prager R, Gaube S, Gisinger C, Schnack C, Kuenburg E, et al. Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. *Hypertension*. 1991(1):15-21.

37. Pacy PJ, Dodson PM, Kubicki AJ. Comparison of the hypotensive and metabolic effects of bendrofluazide therapy and a high fibre, low fat, low sodium diet in diabetic subjects with mild hypertension. *Journal of Hypertension*. 1984;2 (2):215-20.
38. Kuo SW, Pei D, Hung YJ, Hsieh AT, Wu LY, Hsieh CH, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. *American Journal of Hypertension*. 2003 01 Aug;16 (8):623-8.
39. Luna B, Feinglos MN. Drug-induced hyperglycemia. *JAMA*. 2001 Oct 24-31;286(16):1945-8.
40. Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. *Cardiovasc Diabetol*. 2012;11:14.
41. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. *QJM*. 2006 Jul;99(7):431-6.
42. Ferner RE. Drug-induced diabetes. *Baillieres Clin Endocrinol Metab*. 1992 Oct;6(4):849-66.
43. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *Bmj*. 2000 Aug 12;321(7258):405-12.
44. Hirst JA, Stevens RJ, Farmer AJ. Changes in HbA1c Level over a 12-Week Follow-up in Patients with Type 2 Diabetes following a Medication Change. *PLoS One*. 2014;9(3):e92458.
45. Whitcroft IA, Thomas JM, Rawsthorne A, Wilkinson N, Thompson H. Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics. *Hormone and metabolic research Supplement series*. 1990:42-6.
46. Hunter SJ, Wiggam MI, Ennis CN, Whitehead HM, Sheridan B, Atkinson AB, et al. Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. *Diabetic Medicine*. 1999 Jun;16(6):482-7.
47. Lewis HM, Kendall MJ, Wright AD, Bratty JR, Maxwell S. A comparison of the metabolic effects of flosequinan and propranolol in patients with non-insulin-dependent diabetes mellitus. *Journal of Clinical Pharmacy and Therapeutics*. 1991;16 (3):161-6.
48. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF. *American Heart Journal*. 2005 January;149 (1):159-67.
49. Profozic V, Coce F, Babic D, Metelko Z, Rao BA, Schinzer S, et al. Metabolic effects of ramipril in non-insulin dependent diabetics with essential hypertension. *Diabetologia Croatica*. 1997(3):135-44.
50. de Boer RA, Doehner W, van der Horst ICC, Anker SD, Babalis D, Roughton M, et al. Influence of Diabetes Mellitus and Hyperglycemia on Prognosis in Patients  $\geq 70$  Years Old With Heart Failure and Effects of Nebivolol (Data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure [SENIORS]). *American Journal of Cardiology*. 2010 01 Jul;106 (1):78-86.e1.
51. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. *Diabetes Care*. 1983 May-Jun;6(3):285-90.
52. Rodda BE. The Timolol Myocardial Infarction Study: an evaluation of selected variables. *Circulation*. 1983 Jun;67(6 Pt 2):I101-6.
53. Larijani B, Afshari M, Astanehi-Ashgari F, Mojtahedi A, Rezaie A, Hosseinneshad A, et al. Effect of short-term carvedilol therapy on salivary and plasma oxidative stress parameters and plasma glucose level in type II diabetes. *Therapy*. 2006 January;3 (1):119-23.
54. Davies JJ, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. *Diabetologia*. 2004 Oct;47(10):1687-94.


55. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. *Diabetes Care*. 2005(9):2106-12.
56. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. *Kidney International*. 2006(3):536-42.
57. Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. *Diabetologia*. 2008(5):762-8.
58. McLaughlin DM, Atkinson AB, Ennis CN, Browne J, Hunter SJ, Sheridan B, et al. Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. *Diabetic Medicine*. 2008 May;25(5):631-4.

## On-line appendix

**Figure A1** – Mean difference in end-point HbA1c of beta-blockers versus placebo (boxes) and pooled estimates (diamond) calculated by the inverse variance fixed effects model. Horizontal bars and diamond widths represent 95% CIs and box sizes indicate relative weights in the analysis



**Figure A2 - Beta-blockers - Adverse events**





**Figure A3** – Mean difference in end-point HbA<sub>1c</sub> (%) with diuretics versus placebo (boxes) and pooled estimates (diamond) calculated by the inverse variance fixed effects model. Horizontal bars and diamond widths represent 95% CIs and box sizes indicate relative weights in the analysis

